Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) have received a consensus rating of “Moderate Buy” from the fifteen research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and twelve have given a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $130.0769.

Several research firms recently commented on ABVX. Wolfe Research set a $136.00 target price on Abivax in a research note on Wednesday, June 3rd. Citigroup reissued an “outperform” rating on shares of Abivax in a research note on Tuesday, June 2nd. BTIG Research reissued a “buy” rating and set a $150.00 target price on shares of Abivax in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a research note on Monday, April 20th. Finally, Wedbush raised Abivax from an “underperform” rating to a “neutral” rating and lowered their target price for the stock from $110.00 to $90.00 in a research note on Tuesday, June 2nd.

Abivax Stock Performance

Shares of NASDAQ ABVX opened at $99.15 on Friday. Abivax has a twelve month low of $5.69 and a twelve month high of $148.83. The stock has a fifty day simple moving average of $114.06 and a 200-day simple moving average of $118.17. The stock has a market capitalization of $7.91 billion, a PE ratio of -19.03 and a beta of 0.69.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The firm had revenue of $1.56 million during the quarter, compared to analyst estimates of $0.40 million. On average, equities analysts predict that Abivax will post -3.4 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ABVX. GHP Investment Advisors Inc. grew its stake in Abivax by 155.6% during the 1st quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock worth $26,000 after purchasing an additional 140 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in Abivax by 4,612.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after purchasing an additional 369 shares in the last quarter. Bank of America Corp DE grew its stake in Abivax by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after purchasing an additional 1,990 shares in the last quarter. Hantz Financial Services Inc. acquired a new position in Abivax during the 3rd quarter worth $52,000. Finally, Caitong International Asset Management Co. Ltd grew its stake in Abivax by 661.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after purchasing an additional 344 shares in the last quarter. 47.91% of the stock is owned by institutional investors and hedge funds.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.